about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Fol­low­ing top-lev­el C-suite de­par­tures, As­cle­tis raids No­var­tis for R&D ex­ec

6 years ago
People
China

'We're ripe': Cyg­nal draws the cur­tain on Flag­ship's lat­est bet on ex­oneur­al bi­ol­o­gy — and $65M in cash

6 years ago
Financing
Startups

NGM Bio un­veils pos­i­tive PhII NASH re­sults to some unim­pressed in­vestors

6 years ago
R&D

Ness Berming­ham looks to lead the wave of RNA edit­ing at new At­las up­start Ko­r­ro Bio

6 years ago
Startups
Cell/Gene Tx

King Keytru­da: Mer­ck­'s PD-1 star scores #1 po­si­tion and $22B+ pre­dic­tion in an­oth­er top 10 block­buster list for 2025

6 years ago
Pharma

Gilead scores PrEP ap­proval for De­scovy — kick­ing off mar­ket­ing push be­fore Tru­va­da gener­ics swarm

6 years ago
Pharma
FDA+

Re­gen­eron dou­bles down on part­ner Adicet's gam­ma delta T cell tech in $80M fi­nanc­ing

6 years ago
Financing
Cell/Gene Tx

ADC Ther­a­peu­tics is­n't go­ing pub­lic in the US af­ter all, while three oth­er biotech IPOs bring in $319M

6 years ago
Financing

Vivek Ra­maswamy en­gi­neers new deal with RTW to take Pe­te Salz­man­n's Im­muno­vant pub­lic

6 years ago
Deals

Neoanti­gen play­er PACT Phar­ma woos Tim Moore from Kite to run tech­ni­cal ops

6 years ago
People
Cell/Gene Tx

No­var­tis stacks more pos­i­tive PhI­II da­ta on Cosen­tyx fran­chise — eye­ing ap­proval in non-ra­di­ograph­ic ax­i­al ...

6 years ago
R&D
Pharma

The time is now: John Cox as­sumes CEO post at Flag­ship-backed Torque, steer­ing cell ther­a­py to clin­i­cal tri­als

6 years ago
People
Cell/Gene Tx

New norm? Three biotechs pen­cil in $100M IPOs

6 years ago
Financing

As­traZeneca's COPD triple ther­a­py slammed by CRL — falling fur­ther be­hind GSK

6 years ago
R&D

Roche sets new dead­line for Spark ac­qui­si­tion as di­vesti­ture spec­u­la­tion brews

6 years ago
Deals

Be­yond BR­CA: As­traZeneca rounds out ES­MO with a case for ex­pand­ed bio­mark­er in prostate can­cer

6 years ago
R&D
Pharma

Agios lines up sol­id PhI­II da­ta to back Tib­sovo's use in bile duct can­cer — ahead of planned sN­DA

6 years ago
R&D
Pharma

Charg­ing at block­buster Ad­vair, No­var­tis boasts topline vic­to­ries for asth­ma drugs in twin PhI­II stud­ies

6 years ago
R&D

Bank­ing on Op­di­vo/Yer­voy com­bo, Bris­tol-My­ers Squibb teas­es out Check­mate-227 again at ES­MO

6 years ago
R&D
Pharma

As­traZeneca her­alds Tagris­so's OS lead over old TKIs in lung can­cer niche

6 years ago
R&D
Pharma

Bris­tol-My­ers Squibb boasts im­pres­sive 5-year melanoma OS da­ta on Op­di­vo/Yer­voy com­bo, though it still can't pin­point ...

6 years ago
R&D

Bris­tol-My­ers Squib­b's Op­di­vo could­n't top­ple Nex­avar in HCC — but will bet­ter safe­ty pro­file win over physi­cians?

6 years ago
R&D
Pharma

A year in­to Al­bert Bourla’s reign, Ian Read leaves all of Pfiz­er in the new CEO’s con­trol

6 years ago
People

Deer­field bets on New York City, blue­prints $635M biotech hub in mid­town Man­hat­tan

6 years ago
Startups
First page Previous page 89909192939495 Next page Last page
A service from the Financial Times